HBM Holdings Limited

HKSE 2142.HK

HBM Holdings Limited Current Liabilities for the year ending December 31, 2023: USD 64.13 M

HBM Holdings Limited Current Liabilities is USD 64.13 M for the year ending December 31, 2023, a -14.54% change year over year. Current liabilities are obligations that are expected to be settled within one year, including accounts payable, short-term debt, and other current liabilities.

HBM Holdings Limited Current Liabilities for the year ending December 31, 2022 was USD 75.04 M, a 82.79% change year over year.
HBM Holdings Limited Current Liabilities for the year ending December 31, 2021 was USD 41.05 M, a 60.67% change year over year.
HBM Holdings Limited Current Liabilities for the year ending December 31, 2020 was USD 25.55 M, a 42.64% change year over year.
HBM Holdings Limited Current Liabilities for the year ending December 31, 2019 was USD 17.91 M, a 90.94% change year over year.

Key data

Date	Current Liabilities	Total Non-Current Liabilities	Shareholders' Equity	Long-Term Debt

HKSE: 2142.HK

HBM Holdings Limited

CEO	Dr. Jingsong Wang M.D., Ph.D.
IPO Date	Dec. 10, 2020
Location	China
Headquarters	Tower A, 12th Floor
Employees	182
Sector	Health Care
Industries Biotechnology Clinical Trials Pharmaceuticals

Description

HBM Holdings Limited, a clinical-stage biopharmaceutical company, engages in the discovery and development of differentiated antibody therapeutics in immunology and oncology disease areas. It is developing Batoclimab (HBM9161), a human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor; Tanfanercept (HBM9036) to treat moderate to-severe dry eye disease; HBM7008, a bispecific antibody targeting tumor Associated antigen; and HBM4003, a human anti-CTLA-4 antibody against cytotoxic T-lymphocyte-associated antigen-4. The company is also developing HBM9022 for the treatment of SARS-COV-2; HBM9302 for the treatment of breast and gastric cancers; HBM7020 for the treatment of multiple myeloma; and HBM1007, HBM1029, HBM7015, HBM7008, and HBM1022 for the treatment of solid tumors. It operates in Mainland China, the United States, Europe, and internationally. The company has collaboration on antibody-drug conjugate projects with LegoChem Biosciences Inc. and Duality Biotherapeutics, Inc. HBM Holdings Limited was incorporated in 2016 and is based in Shanghai, the People's Republic of China.

Key trends

Past 5 years